TEL
+ 86-21-6420 0566
Краткое описание:
№ КАС: 76168-82-6Молекулярная формула: C106H170ClN21O30Молекулярная масса: 2254.079Стандарт:стандарт п...
№ КАС: 76168-82-6
Молекулярная формула: C106H170ClN21O30
Молекулярная масса: 2254.079
Стандарт:стандарт предприятия
Содержание: ≥95.0%
Packaging:100g/BAG
Use to:glycopeptides
Ramoplanin is a lipoglycodepsipeptide antibiotic with unique properties, which makes it valuable in treating certain bacterial infections.
Аспект | Подробнее |
Источник | Produced by Actinoplanes ATCC 33076 |
Химический класс | Lipoglycodepsipeptide |
Администрация | Oral administration (as it has poor systemic absorption, mainly used for local effects in the gastrointestinal tract) |
Распределение | Mainly remains in the gastrointestinal lumen; limited systemic distribution due to poor absorption |
метаболизм | Not well – characterized, but likely undergoes minimal metabolism in the body |
Ликвидация | Excreted mainly in feces, as it is not absorbed systemically to a significant extent |
Экшн | объяснение |
Ингибирование синтеза клеточной стенки | Ramoplanin binds to the lipid – II molecule in the cell wall of Gram – positive bacteria. Lipid – II is a key intermediate in peptidoglycan synthesis. By binding to lipid – II, ramoplanin blocks the transglycosylation step, which is crucial for the elongation of peptidoglycan chains. This disruption in cell wall synthesis leads to cell death. Additionally, it may also interfere with the proper localization of cell wall – synthesizing enzymes. |
категорию | Подробнее |
Клинические применения | Primarily used for the treatment of Clostridioides difficile – associated diarrhea (CDAD). It targets C. difficile in the gastrointestinal tract, helping to reduce the symptoms and recurrence of CDAD. Since it acts locally in the gut, it has the advantage of minimizing systemic side effects while effectively treating the infection at the site of action. |
Побочные эффекты | Generally well – tolerated. Some patients may experience mild gastrointestinal side effects such as nausea, vomiting, and diarrhea, which can be expected considering its action in the gut. However, these side effects are usually less severe compared to some other antibiotics used for CDAD treatment. There is also a low risk of developing resistance, which is an important advantage in the context of treating a difficult – to – treat pathogen like C. difficile. |
Ramoplanin offers a useful option for treating specific gastrointestinal infections, especially those related to C. difficile, with a relatively favorable safety and efficacy profile.